
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc. is poised for growth as prescriptions for GLP-1 drugs, essential for treating overweight or obesity, have surged by 587% from 2019 to 2024, highlighting a growing market opportunity. The company is advancing its manufacturing efforts to support the upcoming FIH Phase 1 trial while expecting scalable capabilities to enhance as the program develops, indicating strong operational momentum. Positive preliminary data from the REMAIN-1 trial further suggests that GLP-1 PGTx could offer significant improvements in blood glucose management and weight control, positioning Fractyl Health favorably within the competitive landscape of metabolic disease therapies.
Bears say
Fractyl Health Inc. faces a challenging financial outlook primarily due to its high cash burn rate, which may escalate with increased development and commercial programs, coupled with uncertainty regarding the ability to secure sufficient capital for ongoing projects like the Revita and Rejuva platforms. Additionally, the negative implications of impaired GLP-1 function in type 2 diabetes patients could hinder the effectiveness of the company's proposed therapies, especially considering that the observed circulating GLP-1 levels were significantly lower than those associated with existing pharmacological treatments. This scenario raises concerns about the long-term viability and scalability of Fractyl's therapeutic approaches in a competitive market where patient outcomes and treatment tolerability are critical.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares